2523 Noninvasive biomarkers for inflammatory bowel disease: Drawbacks and potential
OBJECTIVES/SPECIFIC AIMS: Approximately 1.6 million Americans suffer from inflammatory bowel diseases (IBD), ulcerative colitis, and Crohn’s disease. It is a challenge for both physicians and patients alike to manage the disease, primarily due to lack of disease specific biomarkers. Endoscopy remain...
Main Authors: | Vihang Patel, Sherif Seif, Terrence Barrett |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2018-06-01
|
Series: | Journal of Clinical and Translational Science |
Online Access: | https://www.cambridge.org/core/product/identifier/S2059866118001024/type/journal_article |
Similar Items
-
2523
by: Angela Merrifield, et al.
Published: (2017-09-01) -
Proceedings of sessions of the Pirogov Surgical Societies № 2523–2526
by: article Editorial
Published: (2019-06-01) -
Noninvasive markers of inflammatory bowel disease activity
by: A. V. Nikitin, et al.
Published: (2018-08-01) -
PB2523: DI-2-ETHYLHEXYL PHTHALATE (DEHP) INHIBITS HEMOGLOBIN S POLYMERIZATION
by: Rodrigo Abreu Camacho, et al.
Published: (2023-08-01) -
Serum galectins as potential biomarkers of inflammatory bowel diseases.
by: Tony B Yu, et al.
Published: (2020-01-01)